表紙:EZH2阻害剤の世界市場機会、販売、臨床試験の洞察(2026年)
市場調査レポート
商品コード
1021300

EZH2阻害剤の世界市場機会、販売、臨床試験の洞察(2026年)

Global EZH2 Inhibitor Market Opportunity, Sales & Clinical Trials Insight 2026

出版日: | 発行: KuicK Research | ページ情報: 英文 105 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

EZH2阻害剤の世界市場機会、販売、臨床試験の洞察(2026年)
出版日: 2021年08月01日
発行: KuicK Research
ページ情報: 英文 105 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のEZH2阻害剤市場は、110%以上のCAGRで成長し、2026年には10億米ドルを超えると予測されています。同市場の高い成長率は、この分野における広範な研究開発と、承認された薬剤の高い採用率によるものです。さらに、政府によるイニシアチブの高まりや有利な償還政策の策定も、同市場での薬剤の高い普及を確実なものにしています。米国は、高い採用率、研究開発活動の活発化、およびがんの罹患率の増加により、世界のEZH2阻害剤市場を支配すると予想されています。

当レポートは、世界のEZH2阻害剤市場について調査しており、市場機会、成長要因および課題、がん・地域別の市場分析、進行中の臨床試験や研究開発、今後の見通し、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 EZH2阻害剤のイントロダクション

  • 概要
  • EZH2阻害剤の進化

第2章 EZH2阻害剤-作用機序

第3章 がん管理におけるEZH2阻害剤の役割

第4章 世界のEZH2阻害剤市場分析

  • 現在の市場シナリオ
  • 先物市場機会評価

第5章 地域別:世界のEZH2阻害剤市場機会

  • 米国
  • 欧州
  • 日本
  • その他の地域

第6章 がん別:世界のEZH2阻害剤市場機会

  • 類上皮肉腫
  • 非ホジキンリンパ腫
  • 前立腺がん
  • 肺がん
  • 乳がん

第7章 タズベリク(タゼメトスタット)-最初に承認されたEZH2阻害薬

  • 概要
  • 特許の洞察

第8章 タズベリク-商業情報

  • 投与量と価格分析
  • 売上分析

第9章 タズベリク-販売予測(2021-2026)

第10章 EZH2阻害剤市場-進行中の臨床試験

  • フェーズ別
  • ステータス別
  • 地域別

第11章 世界のEZH2阻害剤市場-進行中の研究開発

  • SHR2554
  • リラメトスタット(CPI-1205)
  • GSK2816126
  • PF-06821497
  • バレメトスタットトシレート
  • タゼメトスタット

第12章 世界のEZH2阻害剤臨床パイプラインの概要:企業、適応症およびフェーズ別

  • 前臨床
  • フェーズI/II
  • フェーズIII

第13章 市販のEZH2阻害剤の臨床的洞察:タゼメトスタット

第14章 EZH2阻害剤市場力学

  • EZH2阻害剤市場の成長要因
  • EZH2阻害剤市場の課題

第15章 EZH2阻害剤市場の将来展望

第16章 競合情勢

  • Constellation Pharmaceuticals
  • Daiichi Sankyo
  • Epizyme
  • Eternity Bioscience
  • GSK
  • Jiangsu HengRui Medicine
  • Kainos Medicine
  • OncoFusion
  • Pfizer
図表

List of Tables

  • Table 6-1: Global - Estimated Adoption Rates for Epitheloid Sarcoma Targeting EZH2 Inhibitors, 2021-2026
  • Table 6-2: Global - Estimated Adoption Rates for NHL Targeting EZH2 Inhibitors, 2021-2026
  • Table 6-3: Global - Estimated Adoption Rates for Prostate Cancer EZH2 Inhibitors, 2023-2026
  • Table 6-4: Global - Estimated Adoption Rates for Lung Cancer Targeting EZH2 Inhibitors, 2021-2026
  • Table 6-5: Global - Estimated Adoption Rates for Breast Cancer Targeting EZH2 Inhibitors, 2021-2026

List of Figures

  • Figure 1-1: Historical Development of EZH2 Inhibitors
  • Figure 2-1: EZH2 Gene Mechanism in Cancer Development
  • Figure 2-2: EZH2 Mechanism
  • Figure 2-3: EZH2 Inhibitors - Mode of Action
  • Figure 3-1: Role of EZH2 Inhibitors in Cancer Management
  • Figure 4-1: Global - Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 4-2: Global - Number of Cancer Deaths (Million), 2020, 2025 & 2030
  • Figure 4-3: Global - EZH2 Inhibitors Market Opportunity (US$ Million), 2020-2026
  • Figure 4-4: Global - Cancer Drug Market Opportunity (US$ Billion), 2020-2026
  • Figure 4-5: Global - EZH2 Inhibitors Market by Product (%), 2026
  • Figure 5-1: US - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
  • Figure 5-2: US - EZH2 Inhibitors Market Opportunity (US$ Million), 2020-2026
  • Figure 5-3: US - EZH2 Inhibitors Market by Product (%), 2026
  • Figure 5-4: Europe - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
  • Figure 5-5: Europe - EZH2 Inhibitors Market Opportunity (US$ Million), 2022-2026
  • Figure 5-6: Europe - EZH2 Inhibitors Market by Product (%), 2026
  • Figure 5-7: Japan - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
  • Figure 5-8: Japan - EZH2 Inhibitors Market Opportunity (US$ Million), 2022-2026
  • Figure 5-9: Japan - EZH2 Inhibitors Market by Product (%), 2026
  • Figure 5-10: ROW - EZH2 Inhibitors Market Opportunity (US$ Million), 2022-2026
  • Figure 5-11: ROW - EZH2 Inhibitors Market by Product (%), 2026
  • Figure 6-1: Global - Number of Epitheloid Sarcoma Cases, 2021-2026
  • Figure 6-2: Global - Epitheloid Sarcoma Targeting EZH2 Inhibitors Market Opportunity by 10% Acceptance Rate (US$ Million), 2021-2026
  • Figure 6-3: Global - Epitheloid Sarcoma Targeting EZH2 Inhibitors Market Opportunity by 20% Acceptance Rate (US$ Million), 2021-2026
  • Figure 6-4: Global - Epitheloid Sarcoma Targeting EZH2 Inhibitors Market Opportunity by 30% Acceptance Rate (US$ Million), 2021-2026
  • Figure 6-5: Global - Epitheloid Sarcoma Targeting EZH2 Inhibitors Market Opportunity by 40% Acceptance Rate (US$ Million), 2021-2026
  • Figure 6-6: Global - Epitheloid Sarcoma Targeting EZH2 Inhibitors Market Opportunity by 50% Acceptance Rate (US$ Million), 2021-2026
  • Figure 6-7: Global - Epitheloid Sarcoma Targeting EZH2 Inhibitors Market Opportunity by 60% Acceptance Rate (US$ Million), 2021-2026
  • Figure 6-8: Global - Epitheloid Sarcoma Targeting EZH2 Inhibitors Market Opportunity by 70% Acceptance Rate (US$ Million), 2021-2026
  • Figure 6-9: Global - Epitheloid Sarcoma Targeting EZH2 Inhibitors Market Opportunity by 80% Acceptance Rate (US$ Million), 2021-2026
  • Figure 6-10: Global - Epitheloid Sarcoma Targeting EZH2 Inhibitors Market Opportunity by 90% Acceptance Rate (US$ Million), 2021-2026
  • Figure 6-11: Global - Epitheloid Sarcoma Targeting EZH2 Inhibitors Market Opportunity by 100% Acceptance Rate (US$ Million), 2021-2026
  • Figure 6-12: Global - Number of NHL Cases, 2021-2026
  • Figure 6-13: Global - NHL Targeting EZH2 inhibitors Market Opportunity (US$ Million), 2020 - 2026
  • Figure 6-14: Global - Number of Prostate Cancer Cases (Million), 2021-2026
  • Figure 6-15: Global - Prostate Cancer Targeting EZH2 inhibitors Market Opportunity (US$ Million), 2023 - 2026
  • Figure 6-16: Global - Number of Newly Diagnosed Lung Cancer Cases (Million), 2020-2026
  • Figure 6-17: Global - Lung Cancer Targeting EZH2 inhibitors Market Opportunity (US$ Million), 2024 - 2026
  • Figure 6-18: Global - Number of Newly Diagnosed Breast Cancer Cases (Million), 2021-2026
  • Figure 6-19: Global - Breast Cancer Targeting EZH2 inhibitors Market Opportunity (US$ Million), 2023 - 2026
  • Figure 7-1: Tazverik -Approval Year by Region
  • Figure 7-2: Tazverik - Approval Year by Region
  • Figure 8-1: Tazverik - Price for 240 tablets Supply & Price Per Unit of Oral Tablet (US$), July'2021
  • Figure 8-2: Tazverik - Recommended Initial & Reduced Dose (mg/Twice Daily)
  • Figure 8-3: Tazverik - Cost of Daily, Monthly & Annual Treatment (US$), July'2021
  • Figure 8-4: Global - Tazverik Quarterly Sales (US$ Million), 2020
  • Figure 8-5: Global - Tazverik Q1 Sales (US$ Million), 2020 & 2021
  • Figure 9-1: Global - Tazverik Sales Forecast (US$ Million), 2020 - 2026
  • Figure 9-2: US - Tazverik Sales Forecast (US$ Million), 2020 - 2026
  • Figure 9-3: Europe - Tazverik Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-4: Japan - Tazverik Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-5: ROW - Tazverik Sales Forecast (US$ Million), 2021 - 2022
  • Figure 9-6: Global - Tazverik Sales Forecast by Region (%) 2026
  • Figure 10-1: Global - Number of EZH2 Inhibitors Related Clinical Trials by Phase, July'2021
  • Figure 10-2: Global -EZH2 Inhibitors Related Clinical Trials by Phase (%), July'2021
  • Figure 10-3: Global - Number of EZH2 Inhibitors Related Clinical Trials by Development Status, July'2021
  • Figure 10-4: Global -EZH2 Inhibitors Related Clinical Trials by Phase (%), July'2021
  • Figure 10-5: Global - Number of EZH2 Inhibitors Related Clinical Trials by Region, July'2021
  • Figure 11-1: Investigational EZH2 Inhibitors
  • Figure 11-2: SHR2554 Phase III Trial - Study Initiation & Completion Year
  • Figure 11-3: SHR2554 Phase I/II Trial - Study Initiation & Completion Year
  • Figure 11-4: CPI-1205 Phase II Trial - Study Initiation & Completion Year
  • Figure 11-5: PF06821947Phase I Trial - Study Initiation & Completion Year
  • Figure 11-6: Valemetostat Phase I Trial - Study Initiation & Completion Year
  • Figure 11-7: Valemetostat Phase II Trial - Study Initiation & Completion Year
  • Figure 11-8: Valemetostat Phase II Leukemia Trial - Study Initiation & Completion Year
  • Figure 11-9: Valemetostat Phase I Combinational Trial - Study Initiation & Completion Year
  • Figure 11-10: EZH-302 Phase III Trial - Study Initiation & Completion Year
  • Figure 11-11: EZH1401 Phase II Trial - Study Initiation & Completion Year
  • Figure 11-12: EZH301 Phase II Trial - Study Initiation & Completion Year
  • Figure 11-13: EZH1101 Phase II Trial - Study Initiation & Completion Year
  • Figure 12-1: Global - Number of EZH2 Inhibitor Drugs in Clinical Trials by Phase, August'2021
  • Figure 12-2: Global - Number of EZH2 Inhibitor Drugs in Clinical Trials by Country, August'2021
  • Figure 12-3: Global - Number of EZH2 Inhibitor Drugs in Clinical Trials by Company, August'2021
  • Figure 12-4: Global - Number of EZH2 Inhibitor Drugs in Clinical Trials by Indication, August'2021
  • Figure 14-1: Global EZH2 Market Drivers
  • Figure 14-2: Challenges for Global EZH2 Inhibitors Market
  • Figure 14-3: US - Annual Treatment Cost Using Various Drugs (US$), July'2021
  • Figure 16-1: Constellation Pharmaceuticals - Clinical Pipeline
  • Figure 16-2: Eternity Bioscience - Clinical Pipeline
目次

"Global EZH2 Inhibitor Market Opportunity, Sales & Clinical Trials Insight 2026" Report Highlights:

  • Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026
  • Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug
  • Dosage, Price & Sales Analysis of Tazverik
  • Tazverik Sales Opportunity > US$ 900 Million by 2026
  • Tazverik Sales Forecast 2021 Till 2026
  • EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication & Phase
  • EZH2 Inhibitor in Clinical Trials: 7 Drugs

The advent of next generation sequencing has led to identification of multiple novel molecular alterations in cancer. Since the identification of DNA methylation and histone modification, it has now become evident that genes encoding epigenetic modifiers that locally and globally regulate gene expression play a crucial role in normal development and cancer progression. The field of cancer epigenetics has recently gained considerable interest due to role of epigenetic genes in progression of cancer as well as increasing ability to target these genes. In recent times, the histone methyltransferase enhancer of zeste homolog 2 (EZH2), which is enzymatic catalytic subunit of polycomb repressive complex 2 has emerged as a potential therapeutic target.

"EZH2 Inhibitors Market Opportunity Is Expected to surpass USD 1 billion By 2026 From USD 11 million In 2020"

Tazemetostat (Tazverik) is an EZH2 inhibitor which has recently gained approval by US FDA. The drug Tazverik is developed by Epizyme Inc. and is indicated to treat patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Apart from this, the drug is also approved for the management of adult patients with relapsed or refractory follicular lymphoma, who have no satisfactory alternate options. Currently, the drug has been approved in US and Japan and has received orphan designation in Europe. Moreover, the clinical trials with the drug have demonstrated encouraging overall survival rate and positive response rate.

The accelerated approval of Tazemetostat in the management of cancer is thought to revolutionize the overall paradigm of cancer treatment. The global Tazemetostat market was valued around US$ 11.4 Million in 2020 and is expected to witness absolute growth of more than 8000% by 2026. This is mainly due to the robust sales of the drug in short span of time as well as high adoption rates in US market. The integration of EZH2 drug in other therapeutic conditions such as prostate cancer, ovarian cancers and other solid tumors will also aid in boosting the future growth trajectory of the market. Apart from this, it is expected that the drug will gain approval in other regions which will further propel the growth of market.

In coming years, the global market will witness increase in prevalence of cancer attributing to several factors including rising geriatric population, smoking, drinking, physical inactivity and poor diet. This will increase the demand of targeted therapies, thus driving the global EZH2 inhibitor drug market. In addition to Tazemetostat, several pharmaceutical companies have developed potential EZH2 inhibitors candidates including GSK126, CPI1205, SHR2554 and others which are present in clinical stage of development and are expected to gain approval during the forecast period.

As per "Global EZH2 Inhibitor Market Opportunity, Sales & Clinical Trials Insight 2026" report findings, the global EZH2 inhibitor drug market will grow with a CAGR of more than 110% and is expected to surpass US$ 1 Billion by 2026. The high growth rates in the market can be justified by the extensive research and development in this sector and the high adoption rates of approved drug. In addition to this, the rising initiative by government and the development of favorable reimbursement policies will also ensure the high uptake of the drug in the market. US is expected to dominate the global EZH2 inhibitor drug market due to high adoption rates, increasing research and development activities as well as increase in prevalence of cancer.

Table of Contents

1. Introduction to EZH2 Inhibitor

  • 1.1. Overview
  • 1.2. Evolution of EZH2 Inhibitor

2. EZH2 Inhibitor - Mechanism of Action

3. Role of EZH2 Inhibitor in Cancer Management

4. Global EZH2 Inhibitor Market Analysis

  • 4.1. Current Market Scenario
  • 4.2. Future Market Opportunity Assessment

5. Global EZH2 Inhibitor Market Opportunity by Region

  • 5.1. US
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. Rest of World

6. Global EZH2 Inhibitor Market Opportunity by Cancer

  • 6.1. Epitheloid Sarcoma
  • 6.2. Non-Hodgkin's Lymphoma
  • 6.3. Prostate Cancer
  • 6.4. Lung Cancer
  • 6.5. Breast Cancer

7. Tazverik (Tazemetostat) - First Approved EZH2 Inhibitor Drug

  • 7.1. Overview
  • 7.2. Patent Insight

8. Tazverick - Commercial Information

  • 8.1. Dosage & Price Analysis
  • 8.2. Sales Analysis

9. Tazverik - Sales Forecast 2021 Till 2026

10. EZH2 Inhibitor Market - On Going Clinical Trials

  • 10.1. By Phase
  • 10.2. By Status
  • 10.3. By Region

11. Global EZH2 Inhibitor Market - Ongoing Research & Development

  • 11.1. SHR2554
  • 11.2. Lirametostat (CPI-1205)
  • 11.3. GSK2816126
  • 11.4. PF-06821497
  • 11.5. Valemetostat Tosylate
  • 11.6. Tazemetostat

12. Global EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication & Phase

  • 12.1. Preclinical
  • 12.2. Phase-I/II
  • 12.3. Phase-III

13. Marketed EZH2 Inhibitor Clinical Insight: Tazemetostat

14. EZH2 Inhibitor Market Dynamics

  • 14.1. EZH2 Inhibitor Market Drivers
  • 14.2. Challenges for EZH2 Inhibitors Market

15. EZH2 Inhibitor Market Future Outlook

16. Competitive Landscape

  • 16.1. Constellation Pharmaceuticals
  • 16.2. Daiichi Sankyo
  • 16.3. Epizyme
  • 16.4. Eternity Bioscience
  • 16.5. GSK
  • 16.6. Jiangsu HengRui Medicine
  • 16.7. Kainos Medicine
  • 16.8. OncoFusion
  • 16.9. Pfizer